Clinical trials: Pregnancy, Prolonged
Renal Cell Carcinoma
A Rollover Protocol for Subjects Previously Treated With AGS-003
The purpose of this study is to evaluate clinical response to AGS-003 alone or in combination with sunitinib therapy.
- Trial name
- NCT01482949
- Testing
- AGS-003
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Argos Therapeutics
Bacterial Vaginosis (BV)
An Open Single-armed Investigation to Evaluate the Safety of pHyph Following a Prolonged Treatment Duration in Adult Women With Bacterial Vaginosis
1. Rationale Bacterial vaginosis (BV) is caused by an overgrowth of bacteria and affects most women at some point. The infections can cause foul-smelling discharge and sometimes itching and burning.
- Trial name
- NCT07394777
- Testing
- pHyph
- Where
- 2 sites in Sweden
- Volunteers
- 32 people
- Sponsor
- Gedea Biotech AB
Labor, Obstetric
Effect of Tafoxiparin to Treat Primary Slow Progress of Labor Including Prolonged Latent Phase and Labor Arrest
The study will be designed as a double-blind, placebo-controlled, parallel-group, dose-finding study with one group treated with placebo and three groups treated with tafoxiparin in three different infusion concentration levels…
- Trial name
- NCT03001193
- Testing
- DF 01, Oxytocin
- Where
- 12 sites in Denmark, Finland and 1 more
- Volunteers
- 361 people, healthy volunteers welcome
- Sponsor
- Dilafor AB
Anemia of End Stage Renal Disease
TARGTEPO Treatment for Anemia in End Stage Renal Disease (ESRD) Patients Undergoing Peritoneal Dialysis (PD)
The objectives of this study are to assess safety and to evaluate the biologic activity of TARGTEPO treatment in Peritoneal Dialysis patients
- Trial name
- NCT02378662
- Testing
- MDGN201 TARGTEPO
- Where
- 2 sites in Israel
- Volunteers
- 2 people
- Sponsor
- Aevi Genomic Medicine, LLC, a Cerecor company
Heart Failure, Edema
Comparing Natriuretic Effects of ER Torsemide to IR Torsemide in Patients With Heart Failure
The primary objective of this study is to learn whether a morning dose of extended-release torsemide enhances renal sodium excretion after lunch (4-8 hours after dosing) compared to immediate-release torsemide.
- Conditions
- Heart Failure, Edema, Pulmonary Congestion, Fluid Overload
- Trial name
- NEXT-HF (NCT06995144)
- Testing
- Extended Release Torsemide Tablets, Immedate Release Torsemide Tablets
- Where
- United States
- Sponsor
- Sarfez Pharmaceuticals, Inc.
Urinary Bladder, Overactive
A Study to Evaluate the Efficacy of Tolterodine Prolonged Release Compared With Propiverine for the Treatment of Korean Patients With Overactive Bladder as Assessed by Ambulatory Urodynamic Monitoring
The purpose of this study is to compare the difference between tolterodine prolonged release (PR) and propiverine in efficacy as assessed by the AUM and to show that tolterodine PR is similar to propiverine with respect to…
- Trial name
- NCT00646880
- Testing
- propiverine, tolterodine PR
- Where
- South Korea
- Volunteers
- 41 people
- Sponsor
- Pfizer
Urothelial Carcinoma, Urothelial Carcinoma Recurrent
uTRACT Jelmyto Registry: A Registry of Patients With Upper Tract Urothelial Cancer (UTUC) Treated With Jelmyto
The purpose of this registry is to evaluate real world experience and outcomes of patients with Upper Tract Urothelial Cancer (UTUC) treated with Jelmyto in the United States.
- Conditions
- Urothelial Carcinoma, Urothelial Carcinoma Recurrent, Urothelial Carcinoma Ureter, Urothelial Carcinoma Ureter Recurrent
- Trial name
- uTRACT (NCT05874921)
- Testing
- Jelmyto (mitomycin) for pyelocalyceal solution
- Where
- 22 sites in United States
- Volunteers
- 450 people
- Sponsor
- UroGen Pharma Ltd.
Pregnancy Related, Labor Long
Establish the uSI Values and End-user Training Material That Will be Used to Guide Oxytocin Dosing Actions
Patients receiving oxytocin for induction or augmentation of labor will be studied with uterine EMG. The results of the EMG will be converted to an oxytocin-associated uterine stimulation index (uSI), which is intended to guide…
- Conditions
- Pregnancy Related, Labor Long, Fetal Distress
- Trial name
- uSI-ranges (NCT04548453)
- Testing
- uterine electromyography
- Where
- United States
- Volunteers
- 51 people, healthy volunteers welcome
- Sponsor
- PreTeL, Inc
Anemia of End Stage Renal Disease
TARGTEPO Treatment for Anemia in PD US Trial
The objectives of this study are to assess safety and to evaluate the biologic activity of TARGTEPO treatment in Peritoneal Dialysis patients
- Trial name
- NCT02468414
- Testing
- MDGN201 TARGTEPO
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Aevi Genomic Medicine, LLC, a Cerecor company
Interstitial Cystitis, Painful Bladder Syndrome
OXN PR vs Placebo in Opioid-naive Subjects Suffering From Severe Pain Due to Bladder Pain Syndrome (BPS)
The study compares the analgesic efficacy of OXN PR vs placebo in opioid-naive subjects suffering from severe pain due to Bladder Pain Syndrome.
- Conditions
- Interstitial Cystitis, Painful Bladder Syndrome, Pain
- Trial name
- NCT01197261
- Testing
- Oxycodone naloxone prolonged release tablets
- Where
- 5 sites in Czechia, Germany and 3 more
- Volunteers
- 120 people
- Sponsor
- Mundipharma Research GmbH & Co KG
Post Date, Induction of Labor
Use of Single Versus Double Foley's Catheter in Pre-induction Cervical Ripening
Cervical ripening should be present before labor induction, which can generally be divided into two categories: pharmacological and mechanical
- Trial name
- NCT05511727
- Testing
- single versus double Foley's catheter in pre-induction cervical ripening
- Where
- Egypt
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Egymedicalpedia
Pregnancy, Labor
Study to Assess Safety and Efficacy of DF01 in Reducing Prolonged Labor
The study is a Proof-of-concept study to evaluate if DF01 can prevent protracted labor. Time to delivery will be measured from the time of at least 3 cm cervix dilatation and 3 contractions of minimum one minute's duration/10…
- Trial name
- NCT00710242
- Testing
- DF01
- Where
- 18 sites in Sweden
- Volunteers
- 263 people
- Sponsor
- Dilafor AB